Abstract Search

ea0025p18 | Bone | SFEBES2011

The long-term safety and efficacy of zoledronic acid in the treatment of osteoporosis: a 3-year, randomized extension to the HORIZON-pivotal fracture trial (PFT)

Eastell Richard , Reid Ian , Cauley Jane , Boonen Steven , Cosman Felicia , Leung Ping Chung , Lakatos Peter , Man Zulema , Cummings Steven , Hue Trisha , Ruzycky MaryEllen , Martinez Ruvie , Su Guoqin , Bucci-Rechtweg Christina , Black Dennis

Treatment with a single annual infusion of zoledronic acid 5 mg (ZOL) for 3 years has been shown to be effective in increasing bone mineral density (BMD) and decreasing fractures. In order to investigate the long-term effects of ZOL, we performed a 3-year extension of the HORIZON-PFT to 6 years. A total of 1233 women who received ZOL for 3 years in the core study were randomly allocated to 3 additional years of ZOL (Z6, n=616) or blinded placebo (Z3P3, n=617). Pr...

0 shares

Endocrine Abstracts

The long-term safety and efficacy of zoledronic acid in the treatment of osteoporosis: a 3-year, randomized extension to the HORIZON-pivotal fracture trial (PFT)

BiosciAbstracts